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PURPOSE. To analyze the release of two fluoroquinolones, ciprofloxacin and moxifloxacin,
from conventional hydrogel (CH) and silicone hydrogel (SH) daily disposable contact lenses
(CLs), comparing release from a fixed-volume vial and a novel in vitro eye model.
METHODS. Four CH CLs (nelfilcon A, omafilcon A, etafilcon A, ocufilcon B) and three SH CLs
(somofilcon A, narafilcon A, delefilcon A) were used. The lenses were incubated in drug
solutions for 24 hours. After the incubation period, the lenses were placed in two release
conditions: (1) a vial containing 4.8 mL PBS for 24 hours and (2) an in vitro eye model with a
flow rate at 4.8 mL over 24 hours.
RESULTS. Release in the vial for both drugs was rapid, reaching a plateau between 15 minutes
and 2 hours for all lenses. In contrast, under physiological flow conditions, a constant and
slow release was observed over 24 hours. The amounts of ciprofloxacin released from the
lenses ranged between 49.6 6 0.7 and 62.8 6 0.3 lg per lens in the vial, and between 35.0 6
7.0 and 109.0 6 5.0 lg per lens in the eye model. Moxifloxacin release ranged from 24.0 6
4.0 to 226.0 6 2.0 lg per lens for the vial, and between 13.0 6 2.0 and 151.0 6 10.0 lg per
lens in the eye model. In both systems and for both drugs, HEMA-based CLs released more
drugs than other materials.
CONCLUSIONS. The parameters of the release system, in particular the volume and flow rate,
have a significant influence on measured release profiles. Under physiological flow, release
profiles are significantly slower and constant when compared with release in a vial.
Keywords: ciprofloxacin, moxifloxacin contact lens, drug delivery, eye model, microfluidic,
silicone hydrogel
Ciprofloxacin and moxifloxacin are important antimicrobialagents for the treatment of a wide range of ocular surface
diseases.1–4 Both drugs are examples of fluoroquinolone agents,
with a wide range of activity against both gram-negative and
gram-positive bacteria.2,3 Their popularity in treating ocular
infection is attributed to their broad spectrum of inhibition,
excellent ocular penetration, and their availability in a wide
form of ophthalmic preparations.2,3 Fluoroquinolones prevent
bacterial DNA multiplication by inhibiting two enzymes that are
essential for chromosome replication: DNA gyrase and DNA
topoisomerase IV.
Ciprofloxacin is the most widely prescribed second-genera-
tion quinolone antibiotic, which came into clinical use in the late
1980s.1 This relatively hydrophobic drug has low solubility at
physiological pH (0.09 mg/mL at pH 7) and increased solubility
in acidic or basic mediums (3.46 mg/mL at pH 5).1 It is currently
available in the form of 0.3% eye drops or 0.3% ointments.
Moxifloxacin is a newer, fourth-generation 8-quinolone5 with an
extended treatment spectrum, as well as increased bacteriostatic
and bactericidal efficacy, when compared with ciprofloxacin.6–9
The drug has superior penetration into the anterior ocular
tissues, and has greater resistance to bacterial efflux mecha-
nisms, due to its bulky side chain moiety.9 Overall, this allows the
drug to accumulate more effectively inside bacterial cells.9
Furthermore, simultaneous mutation to both enzymes by the
pathogen of interest are required to decrease the efficacy of
moxifloxacin, while only one mutation is sufficient to increase
the resistance of pathogens against ciprofloxacin.10 Finally,
another notable improvement of moxifloxacin compared with
its predecessor is improved water solubility at pH 7 (24 mg/
mL).11 It is currently prescribed as 0.5% eye drops for
ophthalmic applications.
Eye drops, although overall convenient with regard to
formulation preparations, are very inefficient as a treatment
regimen, as average drug residence time on the ocular surface is
only 2 to 5 minutes.12 The estimated amount of medicine that is
absorbed by the cornea during that time is only 1% to 7% of the
applied dose, and the rest is effectively washed out by
continuous tear flow from the lacrimal sac into the nasolacrimal
duct, where it is absorbed into the bloodstream.13 This may
lead to undesirable systemic side effects. Moreover, to achieve
therapeutic drug concentrations in the target tissues, drugs
must be applied very frequently in small doses, even during
sleeping hours.14,15 This type of treatment regimen results in
both discomfort and inconvenience for the patient. Therefore,
there is a considerable need for a drug delivery device that can
effectively deliver drugs to the ocular surface for an extended
period of time.
The use of contact lenses (CLs) may be a promising
approach to deliver drugs to the cornea.16,17 Since 1965, CLs
have been proposed as potential drug carriers,17,18 and a great
deal of research has been conducted since then to develop a
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commercial product.19–21 Unfortunately, studies in the past
have shown that unmodified, commercially available CLs
containing drugs rapidly release their drug load within the
first hour.22–24 For this reason, commercial CLs were consid-
ered poor candidates for prolonged drug delivery. However,
previous in vitro models used to measure release rates may not
have reflected the physical parameters found in the ocular
environment. For instance, the tear volume on the corneal
surface is approximately 7 6 2 lL,25 which undergoes a rate of
tear exchange at approximately 0.95 to 1.55 lL/min.26 To date,
much of the published research has performed release
experiments by immersing the lenses in vials containing 2 to
5 mL PBS, with no form of fluid exchange.22,23,27 Because the
mechanism of drug release from unmodified CLs can be
described as primarily simple diffusion, it should not be
surprising that drugs are eluted very quickly when exposed to
large volumes of static fluid. The in vivo release of drugs from
CLs on the ocular surface, which has a lower volume and
constant tear turnover, may be much slower.
To provide a better understanding of the drug release
mechanisms in vivo, we developed an in vitro eye model that
simulates both tear volume and flow. This study highlights the
differences between the standard large volume, static vial
model previously used by researchers, and our in vitro eye
model, by evaluating the release kinetics of ciprofloxacin
(relatively hydrophobic) and moxifloxacin (relatively hydro-
philic) from four commercially available daily disposable




Seven commercially available disposable CLs were used in this
study: four CH CLs (nelfilcon A [Alcon, Fort Worth, TX, USA],
omafilcon A [CooperVision, Scottsville, NY, USA], etafilcon A
[Johnson & Johnson, Jacksonville, FL, USA], and ocufilcon B
[CooperVision]) and three SH lenses (somofilcon A [Cooper-
Vision], narafilcon A [Johnson & Johnson], and delefilcon A
[Alcon]). The lenses were obtained in their original packaging,
and each lens had a dioptric power of3.00 and base curve of
8.5 or 8.6 mm. The properties of the lenses are listed in Tables
1 and 2.
Preparation of Drug Solutions and Incubation
Six lenses of each type were incubated for 24 hours in 3.0 mg/
mL ciprofloxacin solution (Sigma-Aldrich, Oakville, Ontario,
Canada) in PBS. The pH for this drug solution was adjusted
using hydrochloric acid to pH 4.0 to solubilize the drug.
Another six lenses of each type were incubated in 1.0 mg/mL
of moxifloxacin (Selleckchem, Houston, TX, USA) solution in
PBS (pH 7.4) for 24 hours.
Eye Model Release
For the purpose of this study, a novel eye model was created.
Solid works 2013 was used to design the eye model as a
computer-aided drawing file that was printed using three-
dimensional (3-D) printing technology. The resulting 3-D
printed polycarbonate-acrylonitrile-butadiene-styrene molds,
consisting of a ‘‘corneal/scleral’’ section and an ‘‘eye lid’’
piece, can be filled with the desired polymer. In this study,
these molds were filled with polydimethylsiloxane and cured at
758C for 1 hour to obtain the eye model. The spacing between
the eyeball and eyelid allows for approximately 100 lL fluid to
come in contact with the lens. The eye models are connected
to a microfluidic syringe pump (PHD Ultra; Harvard Apparatus,
Holliston, MA, USA), as shown in Figure 1.
After the incubation period, lenses were partially dried on
lens paper and placed into the eye model. Then PBS was
pumped through the model at a rate of 200 lL/h. The flow-
through fluid was collected in a standard 12-well microliter
plate. At specified time intervals, t¼0, 1, 2, 3, 4, 5, 6, 8, 12, 16,
and 24 hours, 200 lL of this solution was withdrawn and
pipetted into a UV- Star transparent plate (Greiner Bio-One,
Frickenhausen, Germany) and measured using the SpectraMax
M5 UV-Vis Spectrophotometer (Molecular Devices, Sunnyvale,
CA, USA). The concentration of ciprofloxacin was measured
TABLE 1. Properties of CH Lenses Used in the Study
Biomedics 1-Day 1-Day Acuvue Moist Proclear 1 Day DAILIES AquaComfort Plus
US adopted name Ocufilcon B Etafilcon A Omafilcon A Nelfilcon A
Manufacturer CooperVision Johnson & Johnson CooperVision Alcon
Water content, % 52 58 60 69
FDA group IV IV II II
Center thickness, mm 0.07 0.08 0.09 0.10
Oxygen permeability, 3 1011 16.8 28.0 33.0 26.0
Principal monomers HEMA, PVP, MA HEMA, MA HEMA, PC, EGDMA PVA, FMA, PEG
EGDMA, ethylene glycol dimethacrylate; FMA, N-formylmethyl acrylamide; PVP, polyvinyl pyrrolidone.
TABLE 2. Properties of SH Lenses Used in the Study
DAILIES TOTAL1 1-DAY ACUVUE TruEye clariti 1 day
US adopted name Delefilcon A Narafilcon A Somofilcon A
Manufacturer Alcon Johnson & Johnson CooperVision
Water content, % 33 (surface >80%) 46 56
FDA group V V V
Center thickness, mm 0.09 0.09 0.07
Oxygen permeability, 3 1011 140 100 60
Oxygen transmissibility, 3 109 156.0 118.0 86.0
Principal monomers Not disclosed MPMDSM, DMA, HEMA, siloxane macromer, TEGDMA, PVP Not disclosed
DMA, N,N-dimethylacrylamide; MPDMS, monofunctional polydimethylsiloxane; TEGDMA, tetraethyleneglycol dimethacrylate.
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FIGURE 1. Schematic of (A) two-piece eye model. (B) Final set up with a microfluidic pump and a collecting well plate and (C) a close-up showing
how the tear fluid flows over the lens on the eye model. (D) A front-view photograph of the eye model.
Fluoroquinolone Release From Contact Lenses IOVS j April 2015 j Vol. 56 j No. 4 j 2236
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933739/ on 03/07/2017
using fluorescence, with excitation and emission wavelengths
at 274 and 451 nm, respectively. The concentration of
moxifloxacin was measured using absorbance at 287 nm.28 A
standard curve for the drug concentration versus fluorescence
was generated in PBS for ciprofloxacin. For moxifloxacin, a
standard curve for drug concentration versus absorbance was
generated in PBS. The samples were diluted as necessary such
that the fluorescence and absorbance values were within the
linear portion of the standard curve.
Vial Release
After the 24-hour drug incubation, lenses were removed from
the drug solution and partially dried on lens paper. The lenses
were then placed in a vial containing 4.8 mL solution of PBS, at
pH 7.4. At specific time intervals, t ¼ 0, 1, 5, 15, and 30
minutes, and 1, 2, 4, 8, 12, 16, and 24 hours, 200 lL of the
sample was withdrawn from the vial and pipetted into a UV-
Star transparent plate (Greiner Bio-One). After each absor-
bance or fluorescence was measured using the SpectraMax M5
UV-Vis Spectrophotometer (Molecular Devices), the sample
solutions were pipetted back into their respective vials.
Statistical Analysis
Statistical analysis was performed using Statistica 8 software
(StatSoft, Tulsa, OK, USA). All data are reported as mean 6 SD,
unless otherwise stated. Repeated measures ANOVA was
performed to determine the differences across various time
points within the same lens material. An ANOVA was
conducted to determine the differences between lens materials
at each time point. Post hoc Tukey multiple comparison tests
were used when necessary. In all cases, values were considered
statistically significant at P less than 0.05. Graphs were plotted
using GraphPad Prism 5 software (GraphPad, La Jolla, CA,
USA).
RESULTS
The total amount of ciprofloxacin and moxifloxacin released
after 24 hours from seven daily disposable CLs are summarized
in Table 3. For both drugs, there were differences in the total
amount of drug released after 24 hours from the vial compared
with the model eye (P < 0.001). The release profile over 24
hours from the vial and in vitro eye model are illustrated in
Figures 2 to 5. In general, hydroxyethyl methacrylate (HEMA)-
based CH lenses released more ciprofloxacin and moxifloxacin
compared with SH lenses (P < 0.001), when measured using
either the vial or the model eye.
For ciprofloxacin, there was a difference in the total
amount of drugs released after 24 hours from the vial
compared with the eye model (P < 0.001). Nelfilcon A had
a lower drug release in the model eye (P < 0.05), whereas
omafilcon A, etafilcon A, and ocufilcon B had a higher drug
release from the model eye (P < 0.001). There was no
significant difference in the release of ciprofloxacin from the
SH lenses between the two release systems. In the vial, most
of the drug release occurred within the first 2 hours and
plateaued thereafter (P < 0.05), as shown in Figure 3.
Narafilcon A (TruEye; Johnson & Johnson) was the only lens









in Eye Model, lg/Lens
CH1-Day Acuvue Moist Etafilcon A 62.4 6 0.6 109 6 5 226 6 2 151 6 10
CHBiomedics 1-Day Ocufilcon B 62.8 6 0.3 106 6 2 218 6 4 150 6 20
CHProclear 1 Day Omafilcon A 60.9 6 0.3 96 6 5 141 6 2 86 6 8
CHDAILIES AquaComfort Plus Nelfilcon A 55.2 6 0.4 35 6 7 37 6 4 35 6 6
SHclariti 1 day Somofilcon A 56.9 6 0.2 63 6 6 36 6 1 35 6 3
SHDAILIES TOTAL1 Delefilcon A 49.6 6 0.7 49 6 1 24 6 4 20 6 1
SH1-DAY ACUVUE TruEye Narafilcon A 52.9 6 0.9 40 6 5 33 6 3 13 6 2
FIGURE 2. Release of ciprofloxacin (lg/lens) from daily disposable commercial CLs in 4.8 mL PBS. The values plotted are the mean 6 SD for three
trials.
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in which an 8-hour drug release was observed in this system.
In contrast, as shown in Figure 4, the drug release was
sustained from the eye model throughout the 24-hour
observation period (P < 0.05). The lenses that released the
highest amount of ciprofloxacin in both systems were
omafilcon A, etafilcon A, and ocufilcon B. However, as shown
in Figure 6, these lenses had a high amount of white drug
precipitates and thus may not be suitable as ocular drug
delivery lenses. The SH CLs with ciprofloxacin remained clear
throughout the experiment.
For moxifloxacin, after 24 hours, the release from the vial
was overall higher than the eye model (P < 0.001). Omafilcon
A, etafilcon A, and ocufilcon B had a higher drug release in the
vial than the eye model (P < 0.001). There were no significant
differences in the amount of moxifloxacin released for the
other lenses between the two systems. In the vial model, the
release of the moxifloxacin rapidly reached a plateau within 1
hour for all SH lenses and nelfilcon A (P < 0.001). Etafilcon A
and ocufilcon B continued to release the drug up to 2 hours
before reaching a plateau. In contrast, in the eye model, the
release of moxifloxacin was sustained over 24 hours for
etafilcon A and ocufilcon B (P < 0.001). Omafilcon A released
at a constant rate of approximately 10 lg/h for 6 hours, after
which the release slowed down to 2 lg/h. Nelfilcon A and SH
lenses reached a plateau in less than 6 hours (P < 0.05). The
other lenses released moxifloxacin for less than 4 hours, after
which time the rate plateaued.
In both experimental systems, materials that released the
highest amounts of moxifloxacin were etafilcon A and
ocufilcon B (which are both HEMA-based, Food and Drug
Administration [FDA] group IV materials with a high water
content and are negatively charged), followed by omafilcon A
(a HEMA-based, FDA group II material with a high water
content but overall neutral charge). Materials that released the
lowest amount of drug in both systems were nelfilcon A (a
polyvinyl alcohol [PVA]-based, FDA group II material with a
high water content and neutral charge), and all SH lenses.
Visually, all of the lenses containing moxifloxacin remained
clear throughout all phases of the experiment.
FIGURE 3. Release of ciprofloxacin (lg/lens) from eye model with a flow rate of 4.8 mL over 24 hours. The values plotted are the mean 6 SD for
three trials.
FIGURE 4. Release of moxifloxacin (lg/lens) from daily disposable commercial CLs in 4.8 mL PBS. The values plotted are the mean 6 SD for three
trials.
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DISCUSSION
The ideal CL device for prolonged drug delivery should be able
to deliver a precise amount of drug over an extended period of
time. Standard release measurements with unmodified com-
mercial lenses showed that commercial CLs would generally
release drugs too rapidly to be clinically useful.22–24 Similar
results were observed in our study, as CLs loaded with either
ciprofloxacin or moxifloxacin would release their contents
within 1 hour when immersed in a vial containing 4.8 mL
FIGURE 5. Release of moxifloxacin (lg/lens) from eye model with a flow rate of 4.8 mL over 24 hours. The values plotted are the mean 6 SD for
three trials.
FIGURE 6. Ciprofloxacin precipitates on CH lenses (omafilcon A, etafilcon A, ocufilcon B).
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saline. However, closer examination of this release setup
clearly reveals that the parameters used are far from similar to
those found on the ocular surface. In particular, there is an
absence of natural tear flow (at 0.95–1.55 lL/min),26 and the
volume in a vial far exceeds that of the ocular surface, which
has a tear film volume of 7 6 2 lL.25 Because the release is
controlled primarily by diffusion of the drug from the CL, these
parameters are crucial in correctly simulating in vivo release
kinetics.
The in vitro eye model presented in this study is a two-piece
model, consisting of a corneal/scleral section and an eyelid
component. These two components, when pushed together,
allow for the simulation of a thin tear film layer, approximately
100 lL in volume. The added microfluidic system to this model
allows for the simulation of physiological tear flow conditions.
As seen from the results, under physiological conditions, there
was no sign of burst drug release, and the overall release was
also significantly slower. Similar results have been observed
from other studies that have examined drug release from CLs in
microfluidic systems.29–32 The model presented in this study
represents a closed eye and lacks a blinking mechanism. It has
recently been shown that the effect of eye blinking can
facilitate drug release from HEMA hydrogels, and thus should
be considered as an important factor affecting ocular drug
delivery.33
In addition to the differences in release profiles between
the two systems, there were also differences in the amounts
of drugs released during 24 hours. Notably, for moxifloxacin,
lenses released up to 40% more drug in a vial than in the eye-
simulation model. This difference may be accounted for by
the fact that the release from the lenses in the eye model may
not have yet reached completion, even after 24 hours. The
experiment was performed for only 24 hours because all of
the CLs used in this experiment were daily disposable CLs,
and thus should not be worn for more than 24 hours.
However, the results suggest that the drugs could probably
be eluted from the lenses for a longer period of time. In
contrast, the release of ciprofloxacin from HEMA-based CH
lenses in a vial was surprisingly lower than in the eye model.
The release of the drug plateaued entirely in the vial-based
system after 2 hours, but visible white precipitation on the
lens surfaces indicates that a substantial quantity of drug still
remained within the material. Although the mechanism is
uncertain, the release likely ceased as the drug concentration
in the CL and the release media reached an equilibrium. In
the eye model, equilibrium was not reached due to the
continual tear flow, and as a result a higher amount of drug
was eluted.
Overall, the CLs that released the highest amount of drugs
were HEMA-based CH lenses. Etafilcon A and ocufilcon B had
the highest drug release, followed by omafilcon A. Etafilcon A
and ocufilcon B consist of HEMA, PVA, and methacrylic acid
(MA), whereas omafilcon A is made from HEMA and PC (2-
methacryloyloxyethyl phosphorylcholine). The results suggest
that materials synthesized from copolymers of MA, such as
ocufilcon B and etafilcon A, tend to release higher amounts of
drug than materials without MA The addition of MA results in a
negative charge for the lens material, which attracts positively
charged amino groups of ciprofloxacin and moxifloxacin. This
finding correlates with previous studies with ciprofloxacin,
which also showed that the presence of MA in the polymer
increases the amount of drugs absorbed and released.13
The results from this study indicate that CH lenses in
general release more drugs than SH lenses, which is similar to
results found in previous studies.22,24 The silicone moieties
within SH lenses produce hydrophobic regions within the lens,
which promotes the deposition of hydrophobic drugs, such as
ciprofloxacin. However, the release of ciprofloxacin from
these lenses into an aqueous environment is minimized
because of the favorable hydrophobic-hydrophobic interaction
between the lens and the drug.24 In addition, it also would be
difficult for water to penetrate these hydrophobic pockets to
elute the drugs. For hydrophilic drugs, such as moxifloxacin,
sorption into SH lenses is unfavorable because of the overall
polymer hydrophobicity. Consequently, because of the lesser
amounts of drugs initially absorbed, SH lenses released less
moxifloxacin overall than CH lenses. Furthermore, the weak
interaction between the drug and the polymer resulted in
faster elution of moxifloxacin from SH lenses. One particular
material, nelfilcon A, was an exception to the observed trend.
Although the material is inherently a conventional hydrogel, it
showed a significantly lower release for both ciprofloxacin and
moxifloxacin compared with other CH lenses. This mechanism
is unclear, but could be linked to the unique wetting agents
within the material. Wetting agents, such as PVA and
polyethylene glycol (PEG), are not cross-linked to the polymer.
Consequently, they occupy space within the polymer matrix,
and reduce the ability of the lens to absorb certain substances,
such as drugs, potentially leading to the lower drug release
observed for nelfilcon A.
In this study, the difference in release kinetics between a
relatively hydrophobic drug (ciprofloxacin) and relatively
hydrophilic drug (moxifloxacin) also was examined. Using
the large-volume vial method, there were no significant
differences in release between the drugs, with both being
released rapidly from the lens within the first hour. This
observation is similar to results previously published by other
researchers using the vial as the release system.22–24 However,
using the in vitro eye model, we observed considerable
differences in release profiles for these drugs. The elution of
drugs into an aqueous media is determined by its water
solubility, and the rate at which the drug reaches equilibrium
between the lens and the solution. For ciprofloxacin, the
solubility is low,1 and the constant flow rate prevents
equilibrium from being reached. As a result, ciprofloxacin
was released at a slow and sustained rate for all lens types
over 24 hours. In contrast, moxifloxacin, which has much
higher solubility,11 showed a much faster drug release.
Etafilcon A and ocufilcon B were the only two lenses able
to release moxifloxacin for 24 hours, whereas omafilcon A
released all the drug within 12 hours. All SHs and narafilcon A
were able to release moxifloxacin for only 4 hours in the eye
model.
Both drugs showed the best release profile with CH HEMA-
based lenses. Unfortunately, for ciprofloxacin, white drug
precipitates formed on the surface of these lenses during the
release phase, rendering them opaque. For this reason, despite
showing ideal release kinetics, CH HEMA-based lenses are not
compatible for ciprofloxacin delivery. The SH lenses, although
releasing a lower quantity of drug, may be more suitable for
ciprofloxacin because they provided sustained release for 24
hours, while remaining transparent.
Minimum inhibitory concentrations for 90% of bacterial
isolates (MIC90) is defined as the concentration required to
inhibit the growth of 90% of organisms. The MIC90 for
ciprofloxacin against common, susceptible, and resistant
ocular pathogens ranges from 0.032 to 128 lg/mL.34 All of
the lenses released sufficient amount of drug to meet the MIC90
concentrations against common and susceptible pathogens
during the entire 24-hour period. However, none of the lenses
released enough drug to kill fluoroquinolone-resistant patho-
gens. For moxifloxacin, MIC90 ranges from 0.047 to 4 lg/mL.34
As in the case of ciprofloxacin, all of the lenses released
enough drug to meet the MIC90 concentrations against
common and susceptible pathogens over the 24-hour period.
For fluoroquinolone-resistant pathogens, such as coagulase-
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negative Staphylococcus or Staphylococcus aureus, only
etafilcon A, ocufilcon B, and omafilcon A were able to release
enough drug to meet the MIC90 criteria for 24 hours. The
remaining lenses were able to release sufficient drug for only 2
to 4 hours.
In conclusion, seven different daily disposable CLs were
evaluated for their release of two fluoroquinolones, ciproflox-
acin and moxifloxacin, in two different release systems. The
results suggest that the release profiles are influenced primarily
by the parameters of the release system. In a vial, drugs are
released rapidly within the first hour, which is consistent with
previous reports. However, using an in vitro eye model that
mimics physiological tear volume and tear flow, drug release
from CLs is observed at a much more constant rate over 24
hours. The release kinetics of drugs from CLs also is affected by
material properties of the lens, as well as the hydrophobicity
and hydrophilicity of the drug. Among all the drug-material
combinations, the most promising was the release of
moxifloxacin from etafilcon A and ocufilcon B. The release
was sustained throughout 24 hours, and the amount of eluted
drug can be considered clinically relevant, as it meets the
MIC90 criteria against common, susceptible, and resistant
ocular pathogens during this time period. Additionally, the
lenses remained visually clear throughout all phases of the
experiment. Future work will improve the in vitro eye model,
and further examine the potential of these CLs to inhibit
microbial growth.
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